Compare ACNT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | SPRO |
|---|---|---|
| Founded | 1945 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.2M | 156.3M |
| IPO Year | 1995 | 2017 |
| Metric | ACNT | SPRO |
|---|---|---|
| Price | $13.90 | $2.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 58.1K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 106.72 | ★ 111.81 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $11.62 | $1.80 |
| 52 Week High | $17.92 | $3.08 |
| Indicator | ACNT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 42.65 |
| Support Level | $13.35 | $2.14 |
| Resistance Level | $14.72 | $2.52 |
| Average True Range (ATR) | 0.50 | 0.26 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 45.17 | 28.64 |
Ascent Industries Co is a specialty chemicals company focused on the development, production, and distribution of tailored, performance-driven chemical solutions. Its customers are spread across energy, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), agriculture, water treatment, pulp and paper, construction, automotive, and other industrial markets. The company's core product portfolio includes surfactants, defoamers, lubricating agents, flame retardants, and specialty intermediates, offered in both petroleum-based and bio-based formulations. Geographically, it generates maximum revenue from the United States, followed by Mexico, Canada, Honduras, Colombia, the Netherlands, Costa Rica, Japan, and other markets.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.